Zydus Life Science Intrinsic Value
ZYDUSLIFE • Healthcare
Current Stock Price
₹891.55
Primary Intrinsic Value
₹1100.88
Market Cap
₹9005 Cr
+100.0%
Upside
Median Value
₹1783.10
Value Range
₹320 - ₹2229
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
ZYDUSLIFE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1100.88 | ₹880.70 - ₹1321.06 | +23.5% | EPS: ₹50.04, Sector P/E: 22x |
| Book Value Method | asset | ₹2228.88 | ₹2005.99 - ₹2451.77 | +150.0% | Book Value/Share: ₹2609.70, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1783.10 | ₹1604.79 - ₹1961.41 | +100.0% | Revenue/Share: ₹2434.46, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1783.10 | ₹1604.79 - ₹1961.41 | +100.0% | EBITDA: ₹8020.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2228.88 | ₹1783.10 - ₹2674.66 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹320.26 | ₹288.23 - ₹352.29 | -64.1% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹773.12 | ₹695.81 - ₹850.43 | -13.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1783.10 | ₹1604.79 - ₹1961.41 | +100.0% | ROE: 18.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1714.14 | ₹1542.73 - ₹1885.55 | +92.3% | EPS: ₹50.04, BVPS: ₹2609.70 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
ZYDUSLIFE Intrinsic Value Analysis
What is the intrinsic value of ZYDUSLIFE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Zydus Life Science (ZYDUSLIFE) is ₹1783.10 (median value). With the current market price of ₹891.55, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹320.26 to ₹2228.88, indicating ₹320.26 - ₹2228.88.
Is ZYDUSLIFE undervalued or overvalued?
Based on our multi-method analysis, Zydus Life Science (ZYDUSLIFE) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.46 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 18.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.66x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Zydus Life Science
Additional stock information and data for ZYDUSLIFE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹6,777 Cr | ₹2,589 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹3,228 Cr | ₹2,482 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹2,689 Cr | ₹2,689 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹2,104 Cr | ₹2,104 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹3,293 Cr | ₹2,876 Cr | Positive Free Cash Flow | 8/10 |